ImmunityBio
http://immunitybio.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ImmunityBio
ImmunityBio Sees Booster Role For Under-The-Tongue COVID-19 Vaccine
In search of a differentiated approach, ImmunityBio’s candidate aims to boostT-cell immune responses via a subcutaneous and oral vaccine combination.
Altimmune Hit By Nasal COVID-19 Vaccine Failure, But Has A Plan B
Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.
Your Annual COVID-19 Vaccine Booster Could Be A Pill Or A Spray
A COVID-19 vaccine in a pill being developed by Vaxart and a nasal spray from Altimmune could offer convenience and maybe even superior immunity compared to injections.
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- NantCell